Methods of treating autoimmune and inflammatory diseases
This invention provides method of treatment of autoimmune diseases and/or inflammatory disorders.
1 . A method of treating or alleviating a symptom of an inflammatory disorder comprising identifying a subject suffering from or at risk of developing said inflammatory disorder and administering to said subject an anti-CD3 antibody.
2 . The method of claim 1 , wherein said anti-CD3 antibody is administered in an amount sufficient to inhibit the expression of an inflammatory cytokine or increase the expression of an anti-inflammatory cytokine.
3 . The method of claim 1 , wherein said anti-CD3 antibody is administered in an amount sufficient to induce immunological suppression.
4 . The method of claim 1 , wherein said anti-CD3 antibody is administered in an amount sufficient to induce immunological tolerance.
5 . The method of claim 1 , wherein said antibody is a monoclonal antibody.
6 . The method of claim 5 , wherein said monoclonal antibody is a fully human monoclonal antibody.
7 . The method of claim 1 , wherein said inflammatory disorder is a chronic inflammatory disorder or an acute inflammatory disorder.
8 . The method of claim 1 , wherein said inflammatory disorder is an autoimmune disease.
9 . The method of claim 1 , wherein said inflammatory disorder is uveitis, vasculitis or atherosclerosis.
10 . The method of claim 1 , wherein said subject is a human or an equine.
11 . The method of claim 1 , further comprising administering to said subject an anti-inflammatory agent or an immunosuppressive agent.
12 . The method of claim 11 , wherein said anti-inflammatory agent or immunosuppressive agent is a corticosteroid, a statin, interferon beta, a nonsteroidal anti-inflammatory drugs (NSAIDs), methotrexate, Cyclosporin A or a disease-modifying anti-rheumatic drugs (DMARDs).
13 . The method of claim 12 , wherein the Cyclosporin A is a cyclosporin microemulsion or tacrolimus.
14 . A method reducing the formation of atherosclerotic plaque on an artery comprising administering to a subject an anti-CD3 antibody.
15 . The method of claim 14 , wherein said anti-CD3 antibody is administered in an amount sufficient to inhibit the expression of an inflammatory cytokine or increase the expression of an anti-inflammatory cytokine in said arterial tissue.
16 . The method of claim 15 , wherein said antibody is a monoclonal antibody.
17 . The method of claim 16 , wherein said monoclonal antibody is a fully human monoclonal antibody.
18 . A method of inhibiting tissue inflammation comprising exposing an inflamed tissue to an anti-CD3 antibody.
19 . The method of claim 18 , wherein said anti-CD3 antibody is administered in an amount sufficient to inhibit the expression of an inflammatory cytokine or increase the expression of an anti-inflammatory cytokine in said inflamed tissue.
20 . The method of claim 18 , wherein said antibody is a monoclonal antibody.
21 . The method of claim 20 , wherein said monoclonal antibody is a fully human monoclonal antibody.
22 . The method of claim 18 , wherein said tissue is vascular tissue or ocular tissue.